Bide Pharmatech (SH:688073) Zheng Quan Zhi Xing·2025-07-02 16:25Core Viewpoint - The company has announced an adjustment to the maximum repurchase price of its shares following the annual equity distribution for 2024, reducing it from RMB 72.30 per share to RMB 71.44 per share, effective from June 9, 2025 [1][3]. Group 1: Share Repurchase Details - The company plans to repurchase its shares through a centralized bidding method on the Shanghai Stock Exchange, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million [2]. - The initial maximum repurchase price was set at RMB 72.30 per share, which has now been adjusted to RMB 71.44 per share due to the implementation of a cash dividend [3][4]. - The adjustment in the repurchase price is calculated based on the cash dividend per share, which is approximately RMB 0.86, and the change in circulating shares is zero since no new shares are issued [4]. Group 2: Financial Implications - With the adjusted maximum repurchase price of RMB 71.44 per share, the estimated number of shares to be repurchased at the upper limit of RMB 100 million would be approximately 1.4 million shares, representing about 0.77% of the company's total share capital [4]. - The company will adhere to relevant regulations during the repurchase period and will disclose information regarding the progress of the repurchase to investors [4].